| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from ANL graph: Reciprocal relationship from BMY graph: Reciprocal relationship from ANL graph: asing by US$5 million as a result of ad… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
asing by US$5 million as a result of advanced payments from customer. Investing activities In 2025, our net cash used in investing activities was US$15.6 million, primarily as a result of purchases o… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from ANL graph: asing by US$5 million as a result of advanced payments from customer. Investing activities In 2025, our net cash used… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
asing by US$5 million as a result of advanced payments from customer. Investing activities In 2025, our net cash used in investing activities was US$15.6 million, primarily as a result of purchases o… |
| KKR |
KKR & Co. Inc. |
72%
|
asing by US$5 million as a result of advanced payments from customer. Investing activities In 2025, our net cash used in investing activities was US$15.6 million, primarily as a result of purchases o… |
| KKR |
KKR & Co. Inc. |
72%
|
Reciprocal relationship from KKR graph: Reciprocal relationship from ANL graph: Reciprocal relationship from KKR graph: Reciprocal relationship from ANL graph: Reciprocal relationship from KKR graph:… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from ANL graph: asing by US$5 million as a result of advanced payments from customer. Investing activities In 2025, our net cash used… |
| NVSEF |
Novartis AG |
72%
|
asing by US$5 million as a result of advanced payments from customer. Investing activities In 2025, our net cash used in investing activities was US$15.6 million, primarily as a result of purchases o… |
| SNYNF |
Sanofi |
72%
|
asing by US$5 million as a result of advanced payments from customer. Investing activities In 2025, our net cash used in investing activities was US$15.6 million, primarily as a result of purchases o… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ANL graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ANL graph: asing by US$5 million as a result o… |
| ADLAI-NORTYE-BIOPHARMA-CO-LTD |
ADLAI-NORTYE-BIOPHARMA-CO-LTD |
62%
|
iness, results of operations and financial condition. In addition, referrals and word of mouth have significantly contributed to our ability to establishing new partnerships. As a result, any negativ… |
| ALPINE-BIOSCIENCE-LTD-ADLAI-NORTYE-PTE-LTD |
ALPINE-BIOSCIENCE-LTD-ADLAI-NORTYE-PTE-LTD |
62%
|
iness, results of operations and financial condition. In addition, referrals and word of mouth have significantly contributed to our ability to establishing new partnerships. As a result, any negativ… |
| ANL-TALENT-LIMITED |
ANL-TALENT-LIMITED |
62%
|
rformance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential information or trade secrets of … |
| ARCHER-FUTURE-LIMITED |
ARCHER-FUTURE-LIMITED |
62%
|
rformance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential information or trade secrets of … |
| BRITISH-VIRGIN-ISLANDS-ANL-TALENT-LIMITED |
BRITISH-VIRGIN-ISLANDS-ANL-TALENT-LIMITED |
62%
|
rformance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential information or trade secrets of … |
| CGEN |
Compugen Ltd. |
62%
|
Reciprocal relationship from CGEN graph: Reciprocal relationship from ANL graph: iness, results of operations and financial condition. In addition, referrals and word of mouth have significantly cont… |
| COGENCY-GLOBAL-INC |
COGENCY-GLOBAL-INC |
62%
|
iness, results of operations and financial condition. In addition, referrals and word of mouth have significantly contributed to our ability to establishing new partnerships. As a result, any negativ… |
| HK-LIMITED |
HK-LIMITED |
62%
|
iness, results of operations and financial condition. In addition, referrals and word of mouth have significantly contributed to our ability to establishing new partnerships. As a result, any negativ… |
| HUMAN-RESOURCES |
HUMAN-RESOURCES |
62%
|
ry is cost containment. In recent years, government authorities and third-party payors, such as private health insurers and health maintenance organizations have attempted to control costs by limitin… |
| HYBIO-PHARMACEUTICAL-CO-LTD |
HYBIO-PHARMACEUTICAL-CO-LTD |
62%
|
asing by US$5 million as a result of advanced payments from customer. Investing activities In 2025, our net cash used in investing activities was US$15.6 million, primarily as a result of purchases o… |
| JIANGSU-AOSAIKANG-PHARMACEUTICAL-CO-LTD |
JIANGSU-AOSAIKANG-PHARMACEUTICAL-CO-LTD |
62%
|
the parent (109,228 ) (51,869 ) (35,528 ) Research and development expenses For the Year Ended December 31, 2023 2024 2025 (revised) US$ US$ US$ (in thousands) CRO service fees 39,612 29,203 21,299 A… |
| NORTYE-TALENT-LIMITED |
NORTYE-TALENT-LIMITED |
62%
|
rformance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential information or trade secrets of … |
| SWITZERLAND-AG |
SWITZERLAND-AG |
62%
|
amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall … |
| U-S-PUBLIC-COMPANY |
U-S-PUBLIC-COMPANY |
62%
|
tific data abroad. If we are unable to obtain necessary approvals in a timely manner, or at all, our research and development of drug candidates may be hindered. If the relevant government authoritie… |
| XIAMEN-BIOTIME-BIOTECHNOLOGY-CO-LTD |
XIAMEN-BIOTIME-BIOTECHNOLOGY-CO-LTD |
62%
|
hts before and after the redomiciliation, please refer to the shareholder notice and related materials filed in connection with the extraordinary general meeting. Risks Relating to Our Business Our b… |
